What are the limitations of the REDUCE-IT study?
The REDUCE-IT study had several limitations. Most of the study subjects were high-risk patients as evidenced by 70% of those enrolled having a history of CVD. Additionally, primary prevention patients represented a minority of those studied and a subgroup analysis of the primary prevention cohort did not find a difference in CV outcomes. The inclusion criteria utilized also limited the study to those with elevated TG levels and 90% of whom were on stable doses of moderate- to high-dose statins for at least four weeks before the intervention. Finally, the composite outcome included coronary revascularization, which some deem as a less clinically valid outcome.